THE ROLE OF CHEMOTHERAPY FOR METASTATIC BREAST CANCER
- 1 April 1999
- journal article
- review article
- Published by Elsevier in Hematology/Oncology Clinics of North America
- Vol. 13 (2) , 415-434
- https://doi.org/10.1016/s0889-8588(05)70063-0
Abstract
No abstract availableKeywords
This publication has 55 references indexed in Scilit:
- Cancer statistics, 1998CA: A Cancer Journal for Clinicians, 1998
- Decreased efficacy of cyclophosphamide, epirubicin and 5-fluorouracil in metastatic breast cancer when reducing treatment duration from 18 to 6 monthsEuropean Journal Of Cancer, 1993
- Strategies for prevention of anthracycline cardiotoxicityCancer Treatment Reviews, 1993
- Patterns of occurrence of second primary non-mammary malignancies in breast cancer patients: results from 1382 consecutive autopsiesSurgical Oncology, 1993
- EpirubicinDrugs, 1993
- “Classical” CMF versus a 3-weekly intravenous CMF schedule in postmenopausal patients with advanced breast cancer: An EORTC Breast Cancer Co-operative Group Phase III Trial (10808)European Journal of Cancer and Clinical Oncology, 1991
- Comparison of short-term and continuous chemotherapy (mitozantrone) for advanced breast cancerThe Lancet, 1990
- Circulating CA 15-3 levels in the postsurgical follow-up of breast cancer patients and in non-malignant diseasesBreast Cancer Research and Treatment, 1989
- Improving the Quality of Life during Chemotherapy for Advanced Breast CancerNew England Journal of Medicine, 1987
- Carcinoembryonic antigen in patients with breast cancer.An adjunctive tool to monitor response and therapyCancer, 1978